Cargando…

Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease

Radioiodinated imaging agents for Aβ amyloid plaque imaging in Alzheimer’s disease (AD) patients have not been actively pursued. Our previous studies employed the “diaza” derivatives [(11)C]TAZA and [(18)F]flotaza in order to develop successful positron emission tomography (PET) imaging agents for A...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Thrisha T., Iguban, Michael H., Melkonyan, Lusine L., Shergill, Jasmine, Liang, Christopher, Mukherjee, Jogeshwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863004/
https://www.ncbi.nlm.nih.gov/pubmed/36677925
http://dx.doi.org/10.3390/molecules28020865
_version_ 1784875229723492352
author Reddy, Thrisha T.
Iguban, Michael H.
Melkonyan, Lusine L.
Shergill, Jasmine
Liang, Christopher
Mukherjee, Jogeshwar
author_facet Reddy, Thrisha T.
Iguban, Michael H.
Melkonyan, Lusine L.
Shergill, Jasmine
Liang, Christopher
Mukherjee, Jogeshwar
author_sort Reddy, Thrisha T.
collection PubMed
description Radioiodinated imaging agents for Aβ amyloid plaque imaging in Alzheimer’s disease (AD) patients have not been actively pursued. Our previous studies employed the “diaza” derivatives [(11)C]TAZA and [(18)F]flotaza in order to develop successful positron emission tomography (PET) imaging agents for Aβ plaques. There is a need for radioiodinated imaging agents for Aβ plaques for single photon emission computed tomography (SPECT) and PET imaging. We report our findings on the preparation of [(124/125)I]IAZA, a “diaza” analog of [(11)C]TAZA and [(18)F]flotaza, and the evaluation of binding to Aβ plaques in the postmortem human AD brain. The binding affinity of IAZA for Aβ plaques was Ki = 10.9 nM with weak binding affinity for neurofibrillary tangles (Ki = 3.71 μM). Both [(125)I]IAZA and [(124)I]IAZA were produced in >25% radiochemical yield and >90% radiochemical purity. In vitro binding of [(125)I]IAZA and [(124)I]IAZA in postmortem human AD brains was higher in gray matter containing Aβ plaques compared to white matter (ratio of gray to white matter was >7). Anti-Aβ immunostaining strongly correlated with [(124)/(125)I]IAZA in postmortem AD human brains. The binding of [(124)/(125)I]IAZA in postmortem human AD brains was displaced by the known Aβ plaque imaging agents. Thus, radiolabeled [(124/123)I]IAZA may potentially be a useful PET or SPECT radioligand for Aβ plaques in brain imaging studies.
format Online
Article
Text
id pubmed-9863004
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98630042023-01-22 Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease Reddy, Thrisha T. Iguban, Michael H. Melkonyan, Lusine L. Shergill, Jasmine Liang, Christopher Mukherjee, Jogeshwar Molecules Article Radioiodinated imaging agents for Aβ amyloid plaque imaging in Alzheimer’s disease (AD) patients have not been actively pursued. Our previous studies employed the “diaza” derivatives [(11)C]TAZA and [(18)F]flotaza in order to develop successful positron emission tomography (PET) imaging agents for Aβ plaques. There is a need for radioiodinated imaging agents for Aβ plaques for single photon emission computed tomography (SPECT) and PET imaging. We report our findings on the preparation of [(124/125)I]IAZA, a “diaza” analog of [(11)C]TAZA and [(18)F]flotaza, and the evaluation of binding to Aβ plaques in the postmortem human AD brain. The binding affinity of IAZA for Aβ plaques was Ki = 10.9 nM with weak binding affinity for neurofibrillary tangles (Ki = 3.71 μM). Both [(125)I]IAZA and [(124)I]IAZA were produced in >25% radiochemical yield and >90% radiochemical purity. In vitro binding of [(125)I]IAZA and [(124)I]IAZA in postmortem human AD brains was higher in gray matter containing Aβ plaques compared to white matter (ratio of gray to white matter was >7). Anti-Aβ immunostaining strongly correlated with [(124)/(125)I]IAZA in postmortem AD human brains. The binding of [(124)/(125)I]IAZA in postmortem human AD brains was displaced by the known Aβ plaque imaging agents. Thus, radiolabeled [(124/123)I]IAZA may potentially be a useful PET or SPECT radioligand for Aβ plaques in brain imaging studies. MDPI 2023-01-15 /pmc/articles/PMC9863004/ /pubmed/36677925 http://dx.doi.org/10.3390/molecules28020865 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Reddy, Thrisha T.
Iguban, Michael H.
Melkonyan, Lusine L.
Shergill, Jasmine
Liang, Christopher
Mukherjee, Jogeshwar
Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
title Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
title_full Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
title_fullStr Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
title_full_unstemmed Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
title_short Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
title_sort development of [(124/125)i]iaza as a new proteinopathy imaging agent for alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863004/
https://www.ncbi.nlm.nih.gov/pubmed/36677925
http://dx.doi.org/10.3390/molecules28020865
work_keys_str_mv AT reddythrishat developmentof124125iiazaasanewproteinopathyimagingagentforalzheimersdisease
AT igubanmichaelh developmentof124125iiazaasanewproteinopathyimagingagentforalzheimersdisease
AT melkonyanlusinel developmentof124125iiazaasanewproteinopathyimagingagentforalzheimersdisease
AT shergilljasmine developmentof124125iiazaasanewproteinopathyimagingagentforalzheimersdisease
AT liangchristopher developmentof124125iiazaasanewproteinopathyimagingagentforalzheimersdisease
AT mukherjeejogeshwar developmentof124125iiazaasanewproteinopathyimagingagentforalzheimersdisease